Do analysts recommend MRVI or STVN?

Maravai LifeSciences presently has a consensus price target of $7.38, indicating a potential downside of 0.87%. Given Maravai LifeSciences' higher possible upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Stevanato Group 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.75

Does the media prefer MRVI or STVN?

In the previous week, Maravai LifeSciences had 1 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Maravai LifeSciences and 7 mentions for Stevanato Group. Maravai LifeSciences' average media sentiment score of 0.51 beat Stevanato Group's score of 0.42 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MRVI or SHC?

In the previous week, Maravai LifeSciences had 5 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Maravai LifeSciences and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.54 beat Maravai LifeSciences' score of 0.51 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sotera Health 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ADPT or MRVI?

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Maravai LifeSciences. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 8 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.51 beat Adaptive Biotechnologies' score of 0.23 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRVI or ALMR?

In the previous week, Alamar Biosciences had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for Alamar Biosciences and 8 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.51 beat Alamar Biosciences' score of 0.24 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor BLFS or MRVI?

In the previous week, BioLife Solutions and BioLife Solutions both had 8 articles in the media. BioLife Solutions' average media sentiment score of 0.69 beat Maravai LifeSciences' score of 0.51 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maravai LifeSciences (MRVI) Competitors

$7.44 +0.23 (+3.19%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.45 +0.01 (+0.13%)

As of 10/9/2026 07:57 PM Eastern

Compare

MRVI vs. STVN, SHC, ADPT, ALMR, and BLFS

Should you buy Maravai LifeSciences stock or one of its competitors? Maravai LifeSciences's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), and BioLife Solutions (BLFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Maravai LifeSciences compare to Stevanato Group?

Maravai LifeSciences (NASDAQ:MRVI) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Stevanato Group has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.40	-$130.77M	-$0.52	N/A
Stevanato Group	€1.23B	4.80	€158.21M	€0.56	34.68

Stevanato Group has a net margin of 10.99% compared to Maravai LifeSciences' net margin of -37.07%. Stevanato Group's return on equity of 10.43% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Stevanato Group	10.99%	10.43%	6.16%

Maravai LifeSciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Maravai LifeSciences had 1 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for Maravai LifeSciences and 7 mentions for Stevanato Group. Maravai LifeSciences' average media sentiment score of 0.51 beat Stevanato Group's score of 0.42 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maravai LifeSciences presently has a consensus price target of $7.38, indicating a potential downside of 0.87%. Given Maravai LifeSciences' higher possible upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Stevanato Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Stevanato Group beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Sotera Health?

Maravai LifeSciences (NASDAQ:MRVI) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Sotera Health has a net margin of 13.44% compared to Maravai LifeSciences' net margin of -37.07%. Sotera Health's return on equity of 40.12% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Sotera Health	13.44%	40.12%	7.55%

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 91.0% of Sotera Health shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 15.4% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Maravai LifeSciences had 5 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Maravai LifeSciences and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.54 beat Maravai LifeSciences' score of 0.51 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sotera Health	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Maravai LifeSciences has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Sotera Health has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Maravai LifeSciences currently has a consensus price target of $7.38, indicating a potential downside of 0.87%. Sotera Health has a consensus price target of $21.50, indicating a potential upside of 19.05%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts clearly believe Sotera Health is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Sotera Health	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Sotera Health has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.40	-$130.77M	-$0.52	N/A
Sotera Health	$1.16B	4.43	$77.94M	$0.57	31.68

Summary

Sotera Health beats Maravai LifeSciences on 14 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adaptive Biotechnologies has a net margin of -20.73% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.70% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Maravai LifeSciences. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 8 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.51 beat Adaptive Biotechnologies' score of 0.23 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Adaptive Biotechnologies presently has a consensus price target of $28.94, suggesting a potential upside of 9.24%. Maravai LifeSciences has a consensus price target of $7.38, suggesting a potential downside of 0.87%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, research analysts plainly believe Adaptive Biotechnologies is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Adaptive Biotechnologies has higher revenue and earnings than Maravai LifeSciences. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	15.26	-$59.50M	-$0.41	N/A
Maravai LifeSciences	$185.74M	10.40	-$130.77M	-$0.52	N/A

Summary

Adaptive Biotechnologies beats Maravai LifeSciences on 12 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to Alamar Biosciences?

Maravai LifeSciences (NASDAQ:MRVI) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Alamar Biosciences had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for Alamar Biosciences and 8 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.51 beat Alamar Biosciences' score of 0.24 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -37.07%. Alamar Biosciences' return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Alamar Biosciences	N/A	N/A	N/A

Alamar Biosciences has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.40	-$130.77M	-$0.52	N/A
Alamar Biosciences	$74.21M	23.63	-$29.82M	-$1.96	N/A

Maravai LifeSciences currently has a consensus price target of $7.38, indicating a potential downside of 0.87%. Alamar Biosciences has a consensus price target of $31.80, indicating a potential upside of 25.84%. Given Alamar Biosciences' higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Alamar Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Alamar Biosciences beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, BioLife Solutions and BioLife Solutions both had 8 articles in the media. BioLife Solutions' average media sentiment score of 0.69 beat Maravai LifeSciences' score of 0.51 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a net margin of 53.29% compared to Maravai LifeSciences' net margin of -37.07%. BioLife Solutions' return on equity of 2.70% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

BioLife Solutions currently has a consensus price target of $31.38, suggesting a potential downside of 18.74%. Maravai LifeSciences has a consensus price target of $7.38, suggesting a potential downside of 0.87%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioLife Solutions has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	19.63	-$4.59M	$1.16	33.28
Maravai LifeSciences	$185.74M	10.40	-$130.77M	-$0.52	N/A

BioLife Solutions has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Summary

BioLife Solutions beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.87B	$10.43B	$7.16B	$13.21B
Dividend Yield	N/A	1.45%	2.53%	16.37%
P/E Ratio	-14.31	32.42	275.30	26.16
Price / Sales	10.40	106.67	635.97	107.50
Price / Cash	17.22	27.23	76.38	53.09
Price / Book	5.10	6.48	11.22	6.33
Net Income	-$130.77M	$56.67B	$3.50B	$382.15M
7 Day Performance	-5.82%	-1.01%	-0.89%	-1.40%
1 Month Performance	10.55%	8.89%	-4.42%	-3.47%
1 Year Performance	133.23%	32.14%	7.03%	1.18%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.1413 of 5 stars	$7.44 +3.2%	$7.38 -0.9%	+125.5%	$1.87B	$185.74M	N/A	415
STVN Stevanato Group	3.3525 of 5 stars	€21.08 -1.5%	N/A	-20.5%	€6.38B	€1.34B	37.63	6,010	Analyst Forecast
SHC Sotera Health	3.9599 of 5 stars	$18.32 -0.7%	$21.50 +17.4%	+14.4%	$5.22B	$1.16B	32.09	3,000	Analyst Upgrade
ADPT Adaptive Biotechnologies	2.5914 of 5 stars	$28.73 +0.8%	$28.06 -2.3%	+69.3%	$4.58B	$276.98M	N/A	624	Insider Trade
ALMR Alamar Biosciences	3.3847 of 5 stars	$33.02 +1.3%	$31.80 -3.7%	N/A	$2.29B	$74.21M	N/A	222	News Coverage Analyst Upgrade Lockup Expiration

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. STVN, SHC, ADPT, ALMR, and BLFS

How does Maravai LifeSciences compare to Stevanato Group?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Summary

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Summary

How does Maravai LifeSciences compare to Alamar Biosciences?

Summary

How does Maravai LifeSciences compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. STVN, SHC, ADPT, ALMR, and BLFS

How does Maravai LifeSciences compare to Stevanato Group?

Which has higher earnings and valuation, MRVI or STVN?

Is MRVI or STVN more profitable?

Which has more volatility and risk, MRVI or STVN?

Does the media prefer MRVI or STVN?

Do analysts recommend MRVI or STVN?

Do institutionals and insiders have more ownership in MRVI or STVN?

Summary

How does Maravai LifeSciences compare to Sotera Health?

Is MRVI or SHC more profitable?

Do institutionals and insiders believe in MRVI or SHC?

Does the media refer more to MRVI or SHC?

Which has more volatility & risk, MRVI or SHC?

Do analysts prefer MRVI or SHC?

Which has preferable valuation & earnings, MRVI or SHC?

Summary

How does Maravai LifeSciences compare to Adaptive Biotechnologies?

Do insiders & institutionals believe in ADPT or MRVI?

Is ADPT or MRVI more profitable?

Does the media favor ADPT or MRVI?

Which has more risk & volatility, ADPT or MRVI?

Do analysts prefer ADPT or MRVI?

Which has preferable valuation and earnings, ADPT or MRVI?

Summary

How does Maravai LifeSciences compare to Alamar Biosciences?

Does the media prefer MRVI or ALMR?

Is MRVI or ALMR more profitable?

Which has higher valuation and earnings, MRVI or ALMR?

Do analysts recommend MRVI or ALMR?

Do institutionals & insiders believe in MRVI or ALMR?

Summary

How does Maravai LifeSciences compare to BioLife Solutions?

Does the media favor BLFS or MRVI?

Is BLFS or MRVI more profitable?

Do analysts recommend BLFS or MRVI?

Do institutionals and insiders hold more shares of BLFS or MRVI?

Which has higher earnings & valuation, BLFS or MRVI?

Which has more risk and volatility, BLFS or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools